Biotechnology

BOAN BIOTECH

Shandong Boan Biotech reaches licensing agreement for dulaglutide injection (BA5101) in US

BOAN BIOTECH released FY2025 Q3 earnings on March 30, 2026 (BJT), with actual revenue of HKD 213.94 M and EPS of HKD -0.0126

BOAN BIOTECH released FY2025 9 Months Earnings on March 30, 2026 (BJT) with actual revenue of HKD 639.9 M and EPS of HKD 0.026

BOAN BIOTECH released FY2025 earnings on March 30 During-Market (BJT), actual revenue HKD 857.78 M (forecast HKD 1.021 B), actual EPS HKD 0.0109 (forecast HKD 0.2854)

BOAN BIOTECH released FY2025 Q4 earnings on March 30 During-Market (BJT), actual revenue HKD 217.63 M, actual EPS HKD -0.0128

BOAN BIOTECH to release FY2025 earnings on March 30 during market hours (BJT), forecast revenue HKD 1.021 B, EPS HKD 0.2854

Luye Pharma Group Issues Convertible Preferred Shares and Transfers Bona Bio Shares

Boan Biologics' self-developed Boyoujing® Receives Marketing Approval from China's NMPA

Boan Biologics' Denosumab Injection UK Market Authorization Application Accepted by MHRA

BOAN BIOTECH released FY2025 Q1 earnings on August 27, 2025 (BJT) with actual revenue of HKD 210.67 M and EPS of HKD 0.0214

Boan Biologics Announces Mid-Year Results: Revenue Growth but Significant Decline in Net Profit

BOAN BIOTECH released FY2025 Q2 earnings on August 27 During-Market (BJT), actual revenue HKD 215.3 M, actual EPS HKD 0.0195

BOAN BIOTECH released FY2025 Semi-Annual Earnings on August 27 During-Market (BJT), actual revenue HKD 425.96 M, actual EPS HKD 0.0386

BOAN BIOTECH to Release FY2025 Semi-Annual Earnings on August 27, 2025 (BJT)

Boan Biologics' Dulaglutide Injection Approved for Market

Boan Biologics sells shares at a 8.78% discount

Hong Kong Stocks Up After Lunch, Innovative Drug Commercial Insurance Directory Launched

Bona Biologics Obtains A Rating in ESG Assessment

Boan Biologics' Innovative Antibody-Drug Conjugate BA1302 Granted FDA Approval for Clinical Trials

BoAn Bio Completes Placement, Raises HK$396 Million

ONE MEDIA GROUP

WT GROUP

ROBOTPHOENIX

GW TIANDI

HAITIAN ANTENNA

DIT GROUP

E-HOUSE ENT

PROSPER FUTURE

MININGLAMP-W

REDCO HEALTHY

06955

Shandong Boan Biotechnology has received approval from China's National Medical Products Administration for its denosumab biosimilar, Boluojia, to treat bone metastases. This expands its use beyond giant cell tumor of bone and enhances its oncology portfolio. The company aims to leverage this approval for international expansion, targeting markets in the U.S., Southeast Asia, and Latin America, supported by strong clinical data and a growing global market for denosumab therapies.

Tip Ranks

Boan Biotech Wins New China Approval for Denosumab Biosimilar, Accelerates Global Push

588130

159615

159837

512010

159992

520880

513700

159849

159102

520690

560600

510660

513120

159892

512290

516500

516930

159316

513060

159859

159506

BOAN BIOTECH announced its 2025 annual performance, with revenue of 785 million RMB (same below), an increase of 8.1% year-on-year. It recorded a net profit of 7.14 million RMB, a decline of 90.2%, with earnings per share of 0.01 RMB. No final dividend will be distributed

AASTOCKS

ChinaAMC SSE STAR Biology and Medicine ETF

China Southern Hang Seng Biotech ETF(QDII)

E Fund CSI Biotechnology Theme ETF

E Fund CSI 300 Health Care ETF

ICBCCS SSE STAR Biology and Medicine ETF

Yinhua CSI Innovative Drugs Industry ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

First Trust NYSE Arca Biotech Index Fd

Ping An CSI Medicine and Medical Device Innovation ETF

Penghua SSE STAR Biology and Medicine ETF

Penghua CSI HK Connect Health Care Composite ETF

China Merchants CSI Biotechnology Theme ETF

Huaan Hang Seng Biotech ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

ChinaAMC SSE Health Care ETF Initiating Fund

GF CSI HK Innovative Drugs Industry ETF(QDII)

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Guotai CSI Bio-medicine ETF

ChinaAMC CSI Biotechnology Theme ETF

Minsheng Royal CSI Biotechnology Theme ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Bosera Hang Seng Health Care ETF(QDII)

Tianhong CNI BIOMEDICINE ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

"Performance" BOAN BIOTECH's annual net profit is 7.14 million RMB, down 90.2%, no dividend declared

China Medical University Hospital (CMUH) has announced a breakthrough in exosome-based drug delivery for Parkinson's disease, collaborating with Ever Supreme Bio Technology and Shine-On Biomedical. They developed the αDAT-EV platform, which can transport therapeutic agents across the blood-brain barrier, targeting affected neural regions. This innovation allows curcumin, known for its neuroprotective properties, to be effectively delivered to the brain. Preclinical studies show promising results in enhancing drug penetration, activating repair mechanisms, and improving motor function in animal models. The platform has potential applications in various CNS disorders and is scalable for future therapies.

prnewswire

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

Hwabao WP CSI Pharmaceuticals ETF

iShares US Pharma

SPDR S&P Biotech

07:43 ET
			
			
				CMUH-Ever Supreme Team Develops World-First Brain-Targeting Exosome Delivering Curcumin Across the Blood-Brain Barrier for Parkinson's Disease

02186

BOAN BIOTECH announced that its controlling shareholder LUYE PHARMA plans to arrange for its wholly-owned subsidiary Shandong Luye Pharma to further transfer 38.5 million H shares in the market on Thursday (22nd) as part of the proposed transfer. In December last year, LUYE PHARMA's wholly-owned subsidiary Luye Geneora issued several exchangeable preferred shares, allowing preferred shareholders to exchange the relevant shares for the existing H shares held by LUYE PHARMA, involving 100.5 million shares

LUYE PHARMA

BOAN BIOTECH's controlling shareholder plans to further transfer 38.5 million shares

BOAN BIOTECH(06955.HK)

Boan Biotech Wins New China Approval for Denosumab Biosimilar, Accelerates Global Push

"Performance" BOAN BIOTECH's annual net profit is 7.14 million RMB, down 90.2%, no dividend declared

07:43 ET CMUH-Ever Supreme Team Develops World-First Brain-Targeting Exosome Delivering Curcumin Across the Blood-Brain Barrier for Parkinson's Disease

BOAN BIOTECH's controlling shareholder plans to further transfer 38.5 million shares